Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.82 EUR | -0.70% | -0.70% | +2.92% |
Mar. 27 | MEDICLIN Aktiengesellschaft Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 22 | Mediclin to Buy Rehabilitation Clinic in Germany | MT |
Strengths
- The company appears to be poorly valued given its net asset value.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company sustains low margins.
- The company is not the most generous with respect to shareholders' compensation.
- Revenue estimates are regularly revised downwards for the current and coming years.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.92% | 145M | - | C | |
-18.46% | 16.85B | B+ | ||
+4.50% | 12.34B | B | ||
+4.98% | 11.77B | B+ | ||
+4.26% | 10.28B | B+ | ||
+24.97% | 8.38B | B | ||
-0.68% | 7.88B | A- | ||
+20.21% | 7.29B | D | ||
+5.48% | 6.75B | B- | ||
+50.68% | 4.69B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MED Stock
- Ratings MEDICLIN AG